Workflow
Ventas(VTR) - 2024 Q4 - Earnings Call Transcript
VTRVentas(VTR)2025-02-13 18:12

Financial Data and Key Metrics Changes - Ventas delivered full year normalized FFO per share of 3.19,exceedingthehighendofguidancerange,representinga73.19, exceeding the high end of guidance range, representing a 7% year-over-year increase [12][44] - Total company same-store cash NOI grew nearly 8% year-over-year in 2024, with shop same-store cash NOI growth of 16% [45][49] - The company ended 2024 with a net debt to EBITDA ratio of 6.0 times, a 90 basis point improvement year-over-year, entering the long-term target leverage range of 5 to 6 times [47] Business Line Data and Key Metrics Changes - Senior housing NOI growth was significant, with same-store cash NOI growing nearly 16%, marking the third consecutive year of double-digit growth [13][45] - The outpatient medical and research business delivered continued compounding growth of 3% in 2024, with research growing 4.6% and outpatient medical increasing 2.6% [45] - The Ventas Investment Management platform (VIM) has over 5 billion in assets under management, contributing to the overall growth strategy [16] Market Data and Key Metrics Changes - The U.S. senior population aged 80 and above is projected to grow by 28% over the next five years, driving significant demand for senior housing [26] - New construction in senior housing markets remains constrained, with inventory growth at historic lows and new construction starts at an all-time low [27] - Approximately 25% of the portfolio is currently below 80% occupancy, indicating substantial growth potential [102] Company Strategy and Development Direction - The company plans to continue driving shop growth and expand its footprint with accretive investments focused on senior housing, expecting shop business to represent over 50% of NOI by year-end 2025 [17][18] - Ventas aims to maintain its competitive advantages through data analytics, operator relationships, and an experienced team, positioning itself well for future growth [28][41] - The company is focused on executing a community refresh program, improving living and working environments to enhance competitive positioning [29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2025, anticipating normalized FFO per share growth of 7% at the midpoint, driven by shop growth [18][48] - The company highlighted favorable conditions for continued success, including compelling secular demand and a favorable pricing environment [20][21] - Management noted that the current labor market for operators has been favorable, with strong hiring and retention [136] Other Important Information - Ventas completed over 2billioninaccretiveinvestmentsfocusedonseniorhousingin2024,selectedfromalargerpipelineofopportunities[14][36]Thecompanyraised2 billion in accretive investments focused on senior housing in 2024, selected from a larger pipeline of opportunities [14][36] - The company raised 2.2 billion in total equity in 2024, with 250millionofunsettledforwardequityavailablefor2025investments[46]Thecompanyexpectstorecycle250 million of unsettled forward equity available for 2025 investments [46] - The company expects to recycle 200 million through capital recycling efforts, primarily from the sale of skilled nursing facilities [92] Q&A Session Summary Question: What is the trajectory for the medical office building side? - Management indicated that they had 15% more leasing than the prior year and expect occupancy gains in 2025 [58] Question: What is Ventas OI telling you about capitalizing on demographic tailwinds? - Management emphasized the importance of data analytics in making investment decisions and ensuring sustained growth opportunities [62] Question: Can you discuss the acquisition strategy targeting stabilized assets? - Management highlighted the unique opportunity to invest in high-quality assets with a combination of yield and growth, maintaining strict investment criteria [68] Question: What does the deal flow look like compared to last year? - Management noted that the pipeline is larger than last year, with increased activity and competition in the market [78] Question: What are the risks around NIH funding changes? - Management expressed confidence in the long-term prospects of biomedical research in the U.S., despite some noise around NIH grants [90] Question: Can you clarify the seasonal pattern in your guidance for 2025? - Management confirmed that they are using historical seasonality in their underwriting for 2025 [100] Question: What percentage of the portfolio is below 80% occupancy? - Management stated that about 25% of the portfolio is below 80% occupancy, indicating growth potential [102] Question: What is the outlook for capital expenditures? - Management expects capital expenditures to continue at a higher level due to increased volume from acquisitions and conversions [144]